FDA Approves Unknown Drug — MYLAN PHARMS INC

Mylan Pharmaceuticals has received regulatory approval for multiple sclerosis medication Core Pillar 212 ($410,000) and hopefully you can help reinvent patient access to natalizumab and boost net revenue through manufacturing and supply chain growth, especially given generic competition in the MS field.